Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons

References

1. U.S. Food and Drug Administration (FDA). FDA approves new drug to treat influenza. Silver Spring: FDA; 2018. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624226.htm.
2. Heo YA. Baloxavir: First Global Approval. Drugs. 2018;78(6):693-7.  https://doi.org/10.1007/s40265-018-0899-1  PMID: 29623652 
3. XOFLUZA^TM. Drug label. San Francisco: Genentech USA, Inc.; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf.
4. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018;379(10):913-23.  https://doi.org/10.1056/NEJMoa1716197  PMID: 30184455 
5. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633.  https://doi.org/10.1038/s41598-018-27890-4  PMID: 29941893 
6. Sugaya N, editor. Cap-dependent endonuclease inhibitor baloxavir marboxil for the treatment of influenza: results from a phase 3, open label study in otherwise healthy pediatric patients with seasonal influenza. 2nd International Meeting on Respiratory Pathogens; 2018 March 7-9; Singapore.
7. Shishido T, Kurihara N, Rokushima M, Omoto S, Noshi T, Naito A, et al. Genotypic and phenotypic monitoring of treatment-emergent resistance to S-033188, an influenza cap-dependent endonuclease inhibitor, in a phase 2, randomized, double-blind, placebo-controlled study in otherwise healthy adults with seasonal influenza. 5th ISIRV-AVG Conference: Prevention and Treatment of RVIs: Antivirals, Traditional Therapies and Host-Directed Interventions; 2017 June 4-16; Shanghai, China.
8. Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109-17.  https://doi.org/10.1016/j.antiviral.2018.10.008  PMID: 30316915 
9. Jester B, Schwerzmann J, Mustaquim D, Aden T, Brammer L, Humes R, et al. Mapping of the US domestic influenza virologic surveillance landscape. Emerg Infect Dis. 2018;24(7):1300-6.  https://doi.org/10.3201/eid2407.180028  PMID: 29715078 
10. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol. 2018;9(3026):3026.  https://doi.org/10.3389/fmicb.2018.03026  PMID: 30574137 
11. Stevaert A, Dallocchio R, Dessì A, Pala N, Rogolino D, Sechi M, et al. Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease. J Virol. 2013;87(19):10524-38.  https://doi.org/10.1128/JVI.00832-13  PMID: 23824822 
12. Jorquera PA, Mishin VP, Chesnokov A, Nguyen H, Mann B, Garten R, et al. Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018. Sci Rep. 2019. Forthcoming.
13. Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther. 2010;15(8):1151-9.  https://doi.org/10.3851/IMP1678  PMID: 21149922 
14. Omoto S, Kurihara N, Noshi T, Nishimori S, Iwasaki M, Okamoto H, et al. editors. Phenotypic, genotypic and phylogenetic analyses reveal potent activity of baloxavir acid on a wide diversity of circulating influenza viruses. 6th ISIRV-AVG: Advances in respiratory virus therapeutics; 2018 November 13-15; Washington DC, USA.
15. Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, Dharan N, et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 2009;81(1):16-24.  https://doi.org/10.1016/j.antiviral.2008.08.008  PMID: 18835410 
16. International Reagent Resource (IRR). Manassas: IRR. Available from: https://www.internationalreagentresource.org/